Tuesday 3 September 2019, Amsterdam
The sector has obvious growth potential, since the majority of the AMD and DR patient population currently still lack any treatment options. This means that there are vast patient populations for manufacturers to target with new AMD and DR products, and new candidates in these areas can hope for fast track status from regulatory bodies.
The lead analyst of the report commented "Another question-mark that hangs over the future of the AMD and DR pharmaceuticals sector is the widespread belief that the best cure for these conditions is not biological or small-molecule drug interventions that can stabilise or reverse disease progression, but rather prevention: a therapeutic approach that can stop AMD and DR developing in the first place is widely seen as the major goal by scientists and clinicians working in the field."
Leading companies featured in the report include Acucela, Inc., Allergan Plc, Bayer AG, F. Hoffman-La Roche, Ltd., GlaxoSmithKline Pharmaceuticals, Ltd., Novartis AG, Pfizer, Inc., Valent Pharmaceuticals International, Plc and other companies.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : firstname.lastname@example.org
back to News